Kazia KZIA 深 沪
已收盘 08-01 16:00:00 美东时间
8.18
-0.200
-2.39%
华盛通- 最 高8.4034
- 今 开8.40
- 成交量 93.65万股
- 最 低 7.40
- 昨 收 8.38
- 总市值 1112.15万
- 52周最高 39.05
- 市盈率 静 --
- 换手率 0.07%
- 52周最低 2.90
- 委 比 -47.06%
- 总股本 135.96万
- 历史最高 744.50
- 量 比 34.20
- 振 幅 11.97%
- 历史最低 3.005
- 每 手 1
- 风险率 0.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kazia Therapeutics Announces At the Market Offering Agreement
Kazia Therapeutics ( ($KZIA) ) has shared an update. On July 25, 2025, Kazia Th...
07-26 05:17
Kazia Therapeutics Announces Preliminary Results From First Patient In Phase 1b Trial Evaluating Combination Regimen Of Paxalisib, Pembrolizumab, And Standard Chemotherapy After Completing Cycle 1 Of Dosing
Kazia Therapeutics (NASDAQ:KZIA) is pleased to announce preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, pembrolizumab (Keytruda®), and standard
07-09 20:03
美股大行评级 | 潜在涨幅超50%，数十家机构大幅上调甲骨文目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1140203048973164544.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Maxim Group：上调Datavault AI(DVLT)评级至"买入"，目标价3美元</p> <p>• 蒙特利尔银行：维持DoubleVerify Holdings(DV)"跑赢大市"评级，目标价从25美元升至26
06-13 09:33
Maxim Group Maintains Buy on Kazia Therapeutics, Maintains $15 Price Target
Maxim Group analyst Jason McCarthy maintains Kazia Therapeutics (NASDAQ:KZIA) with a Buy and maintains $15 price target.
06-12 01:32
Kazia Therapeutics Announces That First Patient Has Been Dosed In Phase 1b Trial Of Paxalisib In Advanced Breast Cancer
Trial is expected to provide key insights on how paxalisib therapy can be combined with established immunotherapies and standard of care chemotherapy to improve patient outcomes in advanced breast cancer Kazia
06-05 20:05
Kazia Therapeutics Re-elects Director Robert Apple at AGM
Kazia Therapeutics ( ($KZIA) ) has shared an update. On May 22, 2025, Kazia The...
05-29 04:52
Kazia Therapeutics Advances Cancer Research Amid Nasdaq Compliance Challenge
The latest update is out from Kazia Therapeutics ( ($KZIA) ). On May 15, 2025, ...
05-15 20:54
Kazia Therapeutics Highlights Recent Progress and Provides Business Update
Awarded research grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to fund research between The Hebrew University of Jerusalem (Hebrew University) and Kazia to explore...
05-15 20:00
快讯 | Kazia Therapeutics-计划将其美国存托股票与普通股的比例更改为一份美国存托股票代表500股普通股
Kazia Therapeutics-Plans to Change Ratio of Its Adss to Ordinary Shares to One ...
04-15 20:35
Kazia Therapeutics sells intellectual property and trademarks rights for Cantrixil
Kazia Therapeutics (NASDAQ:KZIA) announced on Monday the sale of all intellectual property and trademarks rights to Cantrixil for USD $1M. In March 2021, Vivesto licensed the exclusive global developm...
03-31 19:55
